Segall Bryant & Hamill LLC Has $2.66 Million Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Segall Bryant & Hamill LLC decreased its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 23.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,470 shares of the medical instruments supplier’s stock after selling 6,402 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.38% of Mesa Laboratories worth $2,658,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Mesa Laboratories by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 373,397 shares of the medical instruments supplier’s stock worth $40,973,000 after purchasing an additional 3,119 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its stake in Mesa Laboratories by 7.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 6,968 shares of the medical instruments supplier’s stock worth $761,000 after buying an additional 494 shares during the last quarter. EntryPoint Capital LLC increased its holdings in shares of Mesa Laboratories by 35.2% during the first quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier’s stock worth $81,000 after buying an additional 193 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Mesa Laboratories by 6.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier’s stock valued at $316,000 after acquiring an additional 175 shares during the last quarter. Finally, Motley Fool Asset Management LLC boosted its holdings in shares of Mesa Laboratories by 89.3% in the 1st quarter. Motley Fool Asset Management LLC now owns 16,488 shares of the medical instruments supplier’s stock worth $1,809,000 after acquiring an additional 7,779 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Gary M. Owens sold 2,518 shares of Mesa Laboratories stock in a transaction on Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the transaction, the chief executive officer now directly owns 45,888 shares of the company’s stock, valued at $5,213,794.56. This trade represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Brian David Archbold sold 1,499 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $125.00, for a total transaction of $187,375.00. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by company insiders.

Mesa Laboratories Stock Up 8.2 %

NASDAQ:MLAB opened at $109.09 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $141.17. The stock’s fifty day simple moving average is $121.64 and its 200-day simple moving average is $114.56. The firm has a market capitalization of $592.47 million, a P/E ratio of -2.31 and a beta of 0.87.

Mesa Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 29th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.59%. Mesa Laboratories’s payout ratio is currently -1.40%.

Analyst Ratings Changes

MLAB has been the subject of a number of recent analyst reports. Wells Fargo & Company initiated coverage on Mesa Laboratories in a report on Tuesday, August 27th. They set an “underweight” rating and a $120.00 price target for the company. Evercore ISI raised their target price on Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, StockNews.com downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.